Haim Pharma Group Overview
Haim Pharma Group (HPG) is an Israel-based virtual drug development company, advancing stabilized synthetic psilocin as a first-in-class therapy for neurodegenerative diseases. The company’s lead focus is amyotrophic lateral sclerosis (ALS), with a parallel program in Parkinson’s disease (PD). HPG is pioneering an oral enteric-coated psilocin capsule Neurosilin designed for stability and controlled release. A U.S. provisional patent filed in 2025 protects the novel approach to treating neurodegenerative diseases. The therapeutic concept is based on chronic, sub-hallucinogenic dosing, leveraging psilocin’s multimodal mechanisms: serotonin receptor engagement, restoration of glutamatergic balance, neuroplasticity enhancement, mitochondrial protection, and attenuation of neuroinflammation. Together, these actions aim to slow disease progression and stabilize neuronal viability in ALS and PD. HPG has taken a proactive regulatory path, engaging with the FDA and submitting a briefing package in July 2025, outlining its development strategy and clinical roadmap. The company operates through a virtual model, coordinating with global CROs, CDMOs, and academic partners. Its work is guided by experienced clinical and development advisors with deep expertise in neurology, biostatistics, and regulatory strategy. Haim Pharma group is supported by key knowledge leaders in the area of ALS and clinical trials and is committed to redefining the treatment paradigm for ALS leverage psilocin as a personalized, disease-modifying therapy.
Latest News
No news articles.
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $68K |
| Last funding | $60K |
| Stage | Pre-Funding |
| Rounds | 2 |
| Investors | 0 |
Team Members
1
Employees: 1-10
Web & Social Links
| Website | haimpharmagroup.com |
Locations
Hod Hasharon, Israel
Photos & Videos
1 item(s)
Haim Pharma Group Business
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsCore Technology
Materials & SubstancesTags (3)
amyotrophic-lateral-sclerosis-(als)pharma-companiesparkinsonGeographic Markets
United StatesCanadaAustraliaUnited KingdomEuropeIsraelHaim Pharma Group Financials
Non-Equity Funding
Haim Pharma Group Lifecycle
All Events
Haim Pharma Group News
0 articlesNo news articles.
Haim Pharma Group Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 1 |
| Team members | 1 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 7 classification IDs that could be used for matching.
Haim Pharma Group Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 80/100 |
| Missing | sector, funding rounds, news, markets, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 516598612 |
| Creator | Miriam OReilly |
| Creator email | miriamoreilly@haimpharmagroup.com |
| Last update | 2025-09-11T00:00:00.000Z |
| Created | 2025-09-11T00:00:00.000Z |
| Claimed | Yes |